Literature DB >> 24279852

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.

Adrian Llerena1, Pedro Dorado, Ronald Ramírez, Luis R Calzadilla, Eva Peñas-Lledó, Mayra Álvarez, María E G Naranjo, Idilio González, Bárbaro Pérez.   

Abstract

BACKGROUND & AIM: The CYP2D6 -1584C>G polymorphism (rs1080985) has been identified as a major factor for CYP2D6 expression and function, with the mutant -1584G promoter type being consistently associated with significantly greater expression than -1584C. It may therefore be associated with ultrarapid metabolism. The objective of the present study was to explore the relationship between the CYP2D6 -1584C>G polymorphism and the debrisoquine metabolic ratio in healthy volunteers in order to evaluate its potential impact on the ultrarapid CYP2D6 hydroxylation capacity. MATERIALS &
METHODS: The CYP2D6 -1584C>G polymorphism was analyzed in 320 unrelated healthy individuals who were previously phenotyped for debrisoquine hydroxylation.
RESULTS: The metabolic ratio (log10 mean ± standard deviation) of individuals with the -1584G allele was lower than that of individuals with the -1584C allele for carriers of one active CYP2D6 gene (-0.13 ± 0.33 and 0.17 ± 0.52, respectively; p < 0.05) or two active CYP2D6 genes (-0.32 ± 0.39 and -0.20 ± 0.44, respectively; p < 0.05).
CONCLUSION: The presence of the -1584G allele in the promoter region of the CYP2D6 gene was related to a high CYP2D6 hydroxylation capacity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24279852     DOI: 10.2217/pgs.13.181

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  5 in total

Review 1.  Transcriptional Regulation of CYP2D6 Expression.

Authors:  Xian Pan; Miaoran Ning; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2016-10-03       Impact factor: 3.922

Review 2.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

3.  CYP2D6 rs35742686 and rs3892097 Gene Polymorphisms and Childhood Acute Lymphoblastic Leukemia: Relation to Disease Susceptibility in Kashmiri Children.

Authors:  Nidha Sadiq Shapoo; Akbar Masood; Javid R Bhat; A S Bhatia; Idrees A Shah; Bashir A Ganai
Journal:  J Pediatr Genet       Date:  2021-02-19

4.  A tribute to josé maría ("chema") cantú.

Authors:  Victor B Penchaszadeh; Augusto Rojas-Martinez; Adrián Llerena
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

5.  Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China.

Authors:  Mengyuan Liu; Ying Zhang; Ya Ruth Huo; Shuling Liu; Shuai Liu; Junwei Wang; Change Wang; Jinhuan Wang; Yong Ji
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.